What did the Irbesartan Diabetic Nephropathy Trial study?
The Irbesartan Diabetic Nephropathy Trial studied the cardiovascular outcomes in patients with type 2 diabetes and overt nephropathy, as detailed in the Ann Intern Med. 2003 article titled 'Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy' (45). This trial was conducted by the Collaborative Study Group and was a part of the larger study of the effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (N Engl J Med. 2001;345:861 869. doi: 10.1056/NEJMoa011161). The findings of the Irbesartan Diabetic Nephropathy Trial showed that irbesartan was an effective treatment for reducing the risk of cardiovascular events in patients with type 2 diabetes and nephropathy. 